Enthea is creating employer-sponsored benefit plan coverage for both ketamine (KAT) and psychedelic-assisted therapy (PAT). This coverage will allow for reliable, fair and prompt reimbursement for clinical services rendered. We will offer benefit plans to employers starting with ketamine-assisted therapy in 2022. MDMA-assisted therapy coverage is planned for 2023 and psilocybin assisted-therapy coverage for 2024.  

We are currently seeking letters of interest from mental health professionals who wish to explore participating in the Enthea provider network as KAT and/or PAT providers (including therapists and prescribers). If you are interested in learning more, we would love to hear from you.

Please complete the following brief survey and letter of interest. This will allow for a channel of communication to keep you informed about the opportunity of network participation. Of course, your information will be kept confidential. We are a growing organization, so we sincerely appreciate your patience in advance. Thank you for sharing your time with us today.